Research Article
Tolerogenic versus Inflammatory Activity of Peripheral Blood Monocytes and Dendritic Cells Subpopulations in Systemic Lupus Erythematosus
Table 1
Clinical findings in 43 patients with systemic lupus erythematosus (SLE).
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ASLE: Active disease group. ISLE: Inactive disease group. *Lupus severity in accordance with cumulative major organ involvement. **Anti-dsDNA antibodies: low positive (<20 IU); moderately positive (20–50 IU); high positive (>50 IU). ***Azathioprine, mycophenolate mo1etil, cyclosporine, tacrolimus, methotrexate, cyclophosphamide, or rituximab. ****Low dose, upto 10 mg/day; moderate dose, 10–30 mg/day; high dose, more than 30 mg/ day; = sample investigated. |